Share This Page
Drugs in MeSH Category Filaricides
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lederle | HETRAZAN | diethylcarbamazine citrate | TABLET;ORAL | 006459-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Filaricides Market Analysis and Financial Projection
The global market for filariasis treatments and its associated patent landscape reveal critical insights into pharmaceutical trends for neglected tropical diseases (NTDs). Below is a structured analysis of market dynamics and intellectual property developments for drugs classified under NLM MeSH: Filaricides.
Market Dynamics of Filaricides
The filariasis treatment market is experiencing robust growth, driven by increasing disease prevalence and public health interventions:
-
Market Growth:
The market is projected to rise from USD 10.96 billion in 2023 to USD 28.68 billion by 2033, reflecting a 10.1% CAGR[1][5][11]. This expansion is fueled by rising infections in tropical regions, particularly Africa and South Asia, where Wuchereria bancrofti accounts for 99.4% of cases in India[1][5]. -
Key Drivers:
- Mass Drug Administration (MDA) Programs: Annual doses of ivermectin, diethylcarbamazine (DEC), and albendazole form the backbone of WHO-recommended strategies, achieving microfilariae clearance rates up to 96% in triple-drug regimens[3][16].
- Cost-Effectiveness: MDA alone costs USD 112 per DALY averted, making it 8% of India’s GDP per capita, while integrated vector control increases expenses to USD 1.83 per resident[8].
- Government Initiatives: Programs like India’s National Filaria Prevention Programme (2020) and global funding for R&D aim to eliminate lymphatic filariasis by 2030[1][5].
-
Treatment Landscape:
- First-Line Drugs: DEC, ivermectin, and albendazole dominate, with triple therapy (IDA) showing superior efficacy over dual regimens in clinical trials[3][16].
- Emerging Therapies: AWZ1066S (Subiaco Associates) is a late-stage pipeline drug, while nanoparticle-based delivery systems and Wolbachia-targeting antibiotics like doxycycline are under exploration[1][7][15].
-
Regional Challenges:
Unplanned urbanization and climate change amplify mosquito breeding, while co-endemicity with Loa loa in Africa complicates ivermectin use due to encephalopathy risks[15].
Patent Landscape for Filaricides
Patent activity for filaricides reflects broader trends in NTD research and commercialization barriers:
Aspect | Key Findings |
---|---|
Global Patent Trends | Lymphatic filariasis falls into the low-activity category, with <100 patent families filed between 1985–2014[2]. |
Leading Countries | The U.S. (6,154 filings) and China (2,423) dominate, though 50% of patents are inactive, indicating low commercial viability[2][4]. |
Innovation Hubs | U.S. universities (e.g., Columbia, Michigan) lead in core patent citations, focusing on drug delivery and combination therapies[4]. |
Evergreening Practices | Pharma giants like AstraZeneca and Gilead extend monopolies via trivial formulation patents, delaying generic entry[14]. |
Challenges in Drug Development
- Neglect in R&D: Only 0.6% of NTD-related patents target filariasis, with most investments directed toward diseases like dengue[2][4].
- Generic Dominance: Generics constitute 70–80% of private-sector drug markets in LMICs, reducing incentives for novel filaricide development[12].
- Diagnostic Gaps: PCR and ELISA-based tools remain underpatented despite their critical role in monitoring MDA outcomes[1][7].
Strategic Implications
- Policy Priorities: Scaling MDA coverage and integrating vector control (e.g., insecticidal curtains) could accelerate elimination[8].
- R&D Opportunities: Public-private partnerships are vital to advance therapies like moxidectin and gene-editing technologies[15].
- Equity Concerns: Patent pooling and tiered pricing mechanisms are needed to ensure affordable access in low-income regions[14][12].
"The stagnation in filaricide patents underscores the paradox of NTDs: high burden, low commercial interest."
– Adapted from Springer Medizin’s analysis of NTD patent trends[2].
This interplay of market growth and innovation gaps highlights the need for sustained global collaboration to align economic incentives with public health priorities.
References
- https://www.futuremarketinsights.com/reports/filariasis-treatment-market
- https://www.springermedizin.de/patent-landscape-of-neglected-tropical-diseases-an-analysis-of-w/15223934
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10584738/
- https://www.scirp.org/journal/paperinformation?paperid=89601
- https://www.pharmiweb.com/press-release/2024-10-23/global-filariasis-treatment-market-to-reach-usd-2868-billion-by-2032-projected-to-grow-at-101-ca
- https://patents.google.com/patent/US8841330B2/en
- https://www.imarcgroup.com/filariasis-market
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11649082/
- https://meshb.nlm.nih.gov/record/ui?ui=D008118
- https://www.youtube.com/watch?v=o6CTfdx85ys
- https://www.verifiedmarketreports.com/product/filariasis-treatment-market/
- https://pubmed.ncbi.nlm.nih.gov/24098644/
- https://meshb.nlm.nih.gov/record/ui?ui=D008117
- https://www.uclawsf.edu/2020/09/24/patent-drug-database/
- https://pubmed.ncbi.nlm.nih.gov/20847694/
- https://pubmed.ncbi.nlm.nih.gov/30403937/
More… ↓